Medicare Covers GLP-1 Weight-Loss Drugs Starting July 1
Qualifying Medicare beneficiaries gain access to GLP-1 obesity drugs for $50/month beginning July 1, a historic first for the program.
For the first time in the program's history, Medicare will cover GLP-1 weight-loss medications for eligible beneficiaries starting July 1, with out-of-pocket costs capped at $50 per month — a landmark shift that could extend access to millions of older Americans who previously paid hundreds or thousands of dollars annually for the same drugs.
The coverage expansion marks a significant policy turn for Medicare, which had long excluded obesity treatments from its drug benefit. GLP-1 medications, which include widely recognized brand-name drugs that suppress appetite and regulate blood sugar, have surged in popularity over the past several years but remained financially out of reach for many seniors on fixed incomes.
Read more US Senators Demand CFTC Investigate Polymarket's Marketing →
While the $50 monthly cap will make the drugs far more affordable, health experts urge beneficiaries to weigh the benefits against real medical risks before starting treatment. Side effects associated with GLP-1 drugs can include nausea, vomiting, and gastrointestinal distress. Of particular concern for older adults is the potential for significant muscle mass loss alongside fat reduction — a condition that can accelerate age-related physical decline and increase fall risk if not managed with adequate protein intake and resistance exercise.
Seniors considering the medications should consult their primary care physicians or specialists to determine whether they qualify and to establish a monitoring plan that addresses both the metabolic benefits and the physical risks. The $50 monthly cost applies to those who meet Medicare's eligibility criteria, so beneficiaries should verify their specific plan details before assuming coverage.
Continue reading at MarketWatch.com
